Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001628280-22-006570
Filing Date
2022-03-17
Accepted
2022-03-17 17:05:02
Documents
18
Period of Report
2022-03-17
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A cpix-20220317.htm   iXBRL 8-K/A 48269
2 EX-23.1 exhibit231consentofindepen.htm EX-23.1 2262
3 EX-99.1 exhibit991auditedspecialpu.htm EX-99.1 56946
4 EX-99.2 exhibit992unauditedspec.htm EX-99.2 47847
5 EX-99.3 exhibit993unauditedproform.htm EX-99.3 186470
10 GRAPHIC image_0.jpg GRAPHIC 185
  Complete submission text file 0001628280-22-006570.txt   539684

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20220317.xsd EX-101.SCH 2265
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20220317_def.xml EX-101.DEF 13058
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20220317_lab.xml EX-101.LAB 26049
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20220317_pre.xml EX-101.PRE 13936
12 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20220317_htm.xml XML 11015
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-33637 | Film No.: 22749728
SIC: 2834 Pharmaceutical Preparations